Cell and Gene Therapy (CGT) has been identified as one of the priority areas under the ‘Precision Biotherapeutics’ vertical of the BioE3 Policy for ‘fostering high performance Biomanufacturing’. The CGT sector is a rapidly evolving field with transformative potential for treatment of a range of complex and previously untreatable diseases. The potential of this emerging therapeutic modality is highlighted by the increasing number of CGTs which have been approved and are also in the development pipeline. DBT and BIRAC aim to foster an innovation ecosystem for enabling the development of novel CGTs with an emphasis on improving clinical outcomes, enhancing safety, and advancing translational applications in the field. In view of this, DBT and BIRAC invite proposals on “Precision Biotherapeutics-Cell and Gene Therapy”, with the objective to build requisite capabilities and create necessary infrastructure for advancing this field through novel approaches/ technologies, and enabling development of a pipeline of indigenous and affordable CGT candidates.
The proposals are invited under two categories where first category i.e. “Discovery and application oriented Integrated Network research” focuses on demonstration of “Proof -of-concept” and early stage validation (TRL: 3-5) and second category i.e. “Bridging the gaps for scale-up” focuses on early and late-stage development of CGT candidates (TRL: 5-7)
BIRAC TRL definitions - https://www.birac.nic.in/desc_new.php?id=443
Proposals for the Scheme is required to be submitted online only. To submit a proposal online, please log on to the BIRAC website (www.birac.nic.in).
No Hard Copy to be submitted. Proposals submitted online only would be considered.
Extended Last date for Submission of Proposals : 20th March 2025( midnight)
Details of the scheme including eligibility requirements, categories for proposal submission; guidelines for support as grant and loan; agreement templates etc. are available at www.birac.nic.in
Announcement Date: 15-02-2025
Last Submission Date: 20-03-2025